Skip to main content
Clinical Trials/NL-OMON36702
NL-OMON36702
Completed
Not Applicable

on-invasive nodal staging in breast cancer with MRI Lymphography using gadofosveset; a pilot- study. - Gadofosveset in breast cancer

Medisch Universitair Ziekenhuis Maastricht0 sites10 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast cancer
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient with histopathologically confirmed invasive breast cancer about to undergo nodal staging.
  • 2\. Tumor must be a T2 according the TNM 6\-classification.
  • 3\. Willing and able to undergo all study procedures
  • 4\. Has personally provided written informed consent.

Exclusion Criteria

  • 1\. Age \<18,
  • 2\. History of prior chemotherapy
  • 3\. History of prior radiotherapy of the surrounding areas of the axilla.
  • 4\. Pregnancy
  • 5\. Contra indications for MRI such as pacemaker, aneurysm clips or severe claustrophobia.
  • 6\. Allergy to any of the ingredients of Gadofosveset (Vasovist® /Ablavar®)
  • 7\. Being unable to give informed consent in person
  • 8\. Acute or chronic severe renal insufficiency (glomerular filtration rate \<30
  • mL/min/1\.73m2\).
  • 9\. Acute renal insufficiency of any severity due to the hepato\-renal syndrome or in the perioperative liver transplantation period.

Outcomes

Primary Outcomes

Not specified

Similar Trials